glp 1 cancer risk An important article from @americancancersociety about GLP-1 medications and risk. Lots to break down here! #glp1 #cancer GLP-1s tied to lower risk

It occupies a different mechanistic category from cognitive peptides like Semax or energy peptides like NAD+, which means there is no redundancy in combining them

Consistent with the toxicity of isoniazid in slow acetylators, there is an increased incidence of other drug toxicities in subjects carrying defective alleles, such as lupus erythematosus in patients treated with hydralazine or procainamide (Sim et al., 1988), and haemolytic anemia and inflammatory bowel disease after treatment with sulfasalazine (Chen et al., 2007)

Beauty from within: oral administration of a sulfur-containing supplement methylsulfonylmethane improves signs of skin aging

It is worth mentioning that, GLP-1 inhibits glucagon secretion in -cells during hyperglycemia and normal glycemia states, but does not have this effect at low glycemia levels

Lets discuss how to deal with peripheral artery disease

[DOI] [PubMed] [Google Scholar] 6.Nauck MA, Meier JJ